Financial Distress for Acute Lymphoblastic Leukemia

Not currently recruiting at 44 trial locations

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Children's Oncology Group

Must be taking: Induction chemotherapy

Disqualifiers: KMT2A-R, MPAL, Burkitt's, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 2

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to understand the financial stress parents experience when their child undergoes treatment for acute lymphoblastic leukemia (ALL), a type of blood cancer. Researchers will gather information through surveys, interviews, and medical record reviews (Electronic Health Record Review) to track changes in financial worries over time. The goal is to identify ways to reduce this stress in the future. Parents of children newly diagnosed with ALL and starting chemotherapy may be suitable for this study, especially if they communicate in English or Spanish. As an unphased study, this trial offers a unique opportunity for parents to contribute to research that could lead to meaningful support for families facing similar challenges.

Do I need to stop my current medications to join the trial?

The trial information does not specify whether you need to stop taking your current medications. It focuses on parents' financial distress during their child's leukemia treatment.

Why are researchers excited about this trial?

Researchers are excited about this trial because it aims to uncover the financial challenges families face during pediatric acute lymphoblastic leukemia treatment. Unlike standard treatments that focus solely on medical care, this approach combines electronic health record reviews, surveys, and interviews to gain a comprehensive understanding of the financial strain on families. By identifying these stressors, the trial could lead to improved support systems and policies, enhancing the overall well-being of both patients and their families during the treatment journey.

Who Is on the Research Team?

Melissa P Beauchemin

Principal Investigator

Children's Oncology Group

Are You a Good Fit for This Trial?

Inclusion Criteria

REGULARTORY REQUIREMENTS: All institutional and NCI requirements for human studies must be met

All Children's Oncology Group (COG) NCI Community Oncology Research Program (National Cancer Institute [N]CORP) institutions are eligible for participation in this study upon first parent enrollment

Parents of an index child with newly diagnosed with de novo ALL are eligible for this study

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Induction Chemotherapy

Parents complete surveys at the beginning of their child's induction chemotherapy

4-6 weeks

1 visit (in-person)

Maintenance Chemotherapy

Parents complete surveys at the beginning of maintenance chemotherapy

1-2 years

Multiple visits (in-person)

End of Chemotherapy

Parents complete surveys at the end of last chemotherapy

4 weeks

1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Electronic Health Record Review
• Interview
• Survey Administration

How Is the Trial Designed?

Group I: Health Services Research (survey, interview, chart review) Experimental Treatment 3 Interventions

Parents complete surveys over 15-30 minutes at the beginning of their child's induction chemotherapy, at the beginning of maintenance chemotherapy, and at the end of last chemotherapy. Parents may also participate in one-time individual interview over 30-45 minutes. Additionally, children's medical records are reviewed during the study

Who Is Running the Clinical Trial?

Children's Oncology Group

Lead Sponsor

Trials

467

Recruited

241,000+